Prognostic Value of Rb-82 PET Myocardial Perfusion Imaging
Completed
- Conditions
- Cardiac Health
- Registration Number
- NCT01474577
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Brief Summary
The physician would like to see if nuclear cardiac stress tests can predict cardiac health. For example, if a patient has an abnormal stress test, is he or she more likely to have cardiac problems in the future?
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 57
Inclusion Criteria
- Patient > or = to 18 years of age
- Registered patient at MSKCC
- Patient with one or more 82Rb myocardial perfusion stress tests performed at MSKCC, 2008-2011
Exclusion Criteria
- Patient is unwilling to participate
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method correlate scan findings with clinical outcomes 1 year Patients will complete one questionnaire over the phone.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Rb-82 PET imaging in predicting cardiac outcomes post-cancer therapy?
How does Rb-82 PET compare to SPECT in assessing myocardial perfusion for cardiac risk stratification?
Which biomarkers correlate with abnormal Rb-82 PET stress test results in oncology patients?
What adverse events are associated with Rb-82 PET myocardial perfusion imaging in clinical practice?
Are there combination imaging strategies that enhance Rb-82 PET's prognostic value for cardiotoxicity risk?
Trial Locations
- Locations (1)
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
Memorial Sloan-Kettering Cancer Center🇺🇸New York, New York, United States